Invex Therapeutics Past Earnings Performance
Past criteria checks 0/6
Invex Therapeutics's earnings have been declining at an average annual rate of -32.3%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 71.5% per year.
Key information
-32.3%
Earnings growth rate
-23.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 71.5% |
| Return on equity | -113.6% |
| Net Margin | -49,400.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Jun 09
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Jan 11We Think Invex Therapeutics (ASX:IXC) Can Afford To Drive Business Growth
Aug 24Companies Like Invex Therapeutics (ASX:IXC) Are In A Position To Invest In Growth
May 10Companies Like Invex Therapeutics (ASX:IXC) Can Afford To Invest In Growth
Jan 25We're Interested To See How Invex Therapeutics (ASX:IXC) Uses Its Cash Hoard To Grow
Sep 27We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Mar 31Should You Review Recent Insider Transactions At Invex Therapeutics Ltd (ASX:IXC)?
Feb 06We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Dec 15
Revenue & Expenses BreakdownBeta
How Invex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -6 | 2 | 6 |
| 30 Sep 23 | 0 | -7 | 2 | 6 |
| 30 Jun 23 | 0 | -8 | 2 | 7 |
| 31 Mar 23 | 1 | -7 | 1 | 6 |
| 31 Dec 22 | 1 | -6 | 1 | 5 |
| 30 Sep 22 | 0 | -5 | 1 | 4 |
| 30 Jun 22 | 0 | -4 | 1 | 3 |
| 31 Mar 22 | 0 | -3 | 1 | 2 |
| 31 Dec 21 | 0 | -3 | 1 | 2 |
| 30 Sep 21 | 0 | -3 | 1 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -3 | 2 | 1 |
| 31 Dec 20 | 0 | -3 | 2 | 1 |
| 30 Sep 20 | 0 | -3 | 2 | 1 |
| 30 Jun 20 | 0 | -3 | 2 | 2 |
Quality Earnings: IXC is currently unprofitable.
Growing Profit Margin: IXC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IXC is unprofitable, and losses have increased over the past 5 years at a rate of 32.3% per year.
Accelerating Growth: Unable to compare IXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: IXC has a negative Return on Equity (-113.57%), as it is currently unprofitable.